Table 2.
Percentage of CXCR-4 expression on CD34+ cells
| Patient ID | Percent of CXCR-4 on CD34+ |
|---|---|
| Engrafters | |
| 9 | 2.2 |
| 29* | 4.1 |
| 26* | 19.1 |
| 8 | 21.5 |
| 27 | 22.2 |
| 28 | 24.5 |
| 10 | 63.3 |
| 24* | 80.4 |
| 5 | 95.3 |
| 20* | 96.1 |
| 14 | 98.9 |
| Mean ± SD | 48.0 ± 39.0 |
| Nonengrafters | |
| 41 | 4.1 |
| 45* | 8.4 |
| 34* | 22.5 |
| 35 | 34.9 |
| 42 | 54.2 |
| 47 | 65 |
| 44 | 69.5 |
| 46* | 75.9 |
| 43 | 73.4 |
| 39* | 98.5 |
| Mean ± SD | 50.6 ± 9.4 |
AML cells from 21 different patients were labeled with antibodies to CD34 and CXCR-4. CXCR-4 expression is displayed as a percentage of CD34+ cells. There did not seem to be a difference in CXCR-4 expression levels between AML cases capable of NOD/SCID engraftment and those not able to do so. Of note, the highest CXCR-4 expression was observed in a nonengrafter and the lowest was seen in an engrafting AML sample.
Samples tested for intracellular calcium release from CD34+ cells when stimulated with 100 ng/mL SDF-1 as described in “Calcium flux measurement.” Student paired t test: 1.0